OBJECTIVE: To investigate whether the strength of the association between magnetic resonance imaging (MRI) metrics and cognitive outcomes differs between various multiple sclerosis subpopulations. METHODS: A total of 1052 patients were included in this large cross-sectional study. Brain MRI (T1 and T2 lesion volume and brain parenchymal fraction) and neuropsychological assessment (Brief International Cognitive Assessment for Multiple Sclerosis and Paced Auditory Serial Addition Test) were performed. RESULTS: Weak correlations between cognitive domains and MRI measures were observed in younger patients (age≤30 years; absolute Spearman's rho = 0.05-0.21), with short disease duration (<2 years; rho = 0.01-0.21), low Expanded Disability Status Scale [EDSS] (≤1.5; rho = 0.08-0.18), low T2 lesion volume (lowest quartile; <0.59 mL; rho = 0.01-0.20), and high brain parenchymal fraction (highest quartile; >86.66; rho = 0.01-0.16). Stronger correlations between cognitive domains and MRI measures were observed in older patients (age>50 years; rho = 0.24-0.50), with longer disease duration (>15 years; rho = 0.26-0.53), higher EDSS (≥5.0; rho = 0.23-0.39), greater T2 lesion volume (highest quartile; >5.33 mL; rho = 0.16-0.32), and lower brain parenchymal fraction (lowest quartile; <83.71; rho = 0.13-0.46). The majority of these observed results were confirmed by significant interactions (P ≤ 0.01) using continuous variables. INTERPRETATION: The association between structural brain damage and functional cognitive impairment is substantially weaker in multiple sclerosis patients with a low disease burden. Therefore, disease stage should be taken into consideration when interpreting associations between structural and cognitive measures in clinical trials, research studies, and clinical practice.

CORe Department of Medicine University of Melbourne Melbourne Australia

Department of Health Sciences University of Genoa Genoa Italy

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Neurology Royal Melbourne Hospital Melbourne Australia

Department of Radiodiagnostic 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Statistics and Probability University of Economics Prague Czech Republic

Zobrazit více v PubMed

Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 2011;7:332–342. PubMed

Uher T, Blahova‐Dusankova J, Horakova D, et al. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol 2014;261:1735–1744. PubMed

Rocca MA, Amato MP, De Stefano N, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 2015;14:302–317. PubMed

Uher T, Vaneckova M, Sobisek L, et al. Combining clinical and magnetic resonance imaging markers enhances prediction of 12‐year disability in multiple sclerosis. Mult Scler. 2017;23:51–61. PubMed

Morrow SA, Drake A, Zivadinov R, et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol. 2010;24:1131–1145. PubMed

Blahova Dusankova J, Kalincik T, Dolezal T, et al. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler. 2012;18:662–668. PubMed

Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol 2011;24:244–249. PubMed

Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989;39(2 Pt 1):161–166. PubMed

Rovaris M, Filippi M, Falautano M, et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 1998;50:1601–1608. PubMed

Mesaros S, Rocca MA, Riccitelli G, et al. Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp 2009;30:2656–2666. PubMed PMC

Daams M, Steenwijk MD, Schoonheim MM, et al. Multi‐parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long‐standing multiple sclerosis. Mult Scler 2015;22:608–619. PubMed

Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing‐remitting multiple sclerosis. Arch Neurol 2009;66:1144–1150. PubMed

Nielsen AS, Kinkel RP, Madigan N, et al. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology 2013;81:641–649. PubMed PMC

Riccitelli G, Rocca MA, Pagani E, et al. Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Hum Brain Mapp 2011;32:1535–1543. PubMed PMC

Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012;11:1082–1092. PubMed

Houtchens MK, Benedict RH, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007;69:1213–1223. PubMed

Fulton JC, Grossman RI, Udupa J, et al. MR lesion load and cognitive function in patients with relapsing‐remitting multiple sclerosis. AJNR Am J Neuroradiol 1999;20:1951–1955. PubMed PMC

Zivadinov R, De Masi R, Nasuelli D, et al. MRI techniques and cognitive impairment in the early phase of relapsing‐remitting multiple sclerosis. Neuroradiology 2001;43:272–278. PubMed

Lin X, Tench CR, Morgan PS, Constantinescu CS. Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:437–441. PubMed

Heesen C, Schulz KH, Fiehler J, et al. Correlates of cognitive dysfunction in multiple sclerosis. Brain Behav Immun 2010;24:1148–1155. PubMed

Hulst HE, Steenwijk MD, Versteeg A, et al. Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology 2013;80:1025–1032. PubMed

Hulst HE, Gehring K, Uitdehaag BM, et al. Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI? Mult Scler. 2014;20:1131–1134. PubMed

Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003;74:443–446. PubMed PMC

Maghzi AH, Revirajan N, Julian LJ, et al. Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Mult Scler Relat Disord 2014;3:720–727. PubMed

Nourbakhsh B, Nunan‐Saah J, Maghzi AH, et al. Longitudinal associations between MRI and cognitive changes in very early MS. Mult Scler Relat Disord 2016;5:47–52. PubMed

Hyncicova E, Vyhnalek M, Kalina A, et al. Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis. J Neurol 2017;264:482–493. PubMed

Mollison D, Sellar R, Bastin M, et al. The clinico‐radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: a systematic review and meta‐analysis. PLoS ONE 2017;12:e0177727. PubMed PMC

Uher T, Krasensky J, Vaneckova M, et al. A novel semiautomated pipeline to measure brain atrophy and lesion burden in multiple sclerosis: a long‐term comparative study. J Neuroimaging 2017;. https://doi.org/10.1111/jon.12445. PubMed DOI

Kalincik T, Vaneckova M, Tyblova M, et al. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS ONE 2012;7:e50101. PubMed PMC

Benedict RH, Amato MP, Boringa J, et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurology. 2012;12:55. PubMed PMC

Dusankova JB, Kalincik T, Havrdova E, Benedict RH. Cross cultural validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS). Clin Neuropsychol 2012;26:1186–1200. PubMed

Meyer‐Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurology. 2014;25:58. PubMed PMC

Barkhof F, Filippi M. MRI–the perfect surrogate marker for multiple sclerosis? Nat Rev Neurol 2009;5:182–183. PubMed

Satz P. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology. 1993;7:273–295.

Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing‐remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698–1704. PubMed

Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448–460. PubMed

Uher T, Vaneckova M, Sormani MP, et al. Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. Eur J Neurol 2017;24:292–301. PubMed

Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing‐remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773–780. PubMed PMC

De Stefano N, Tomic D, Radue EW, et al. Effect of fingolimod on diffuse brain tissue damage in relapsing‐remitting multiple sclerosis patients. Mult Scler Relat Disord 2016;7:98–101. PubMed

Arnold DL, Fisher E, Brinar VV, et al. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta‐1a in MS. Neurology 2016;87:1464–1472. PubMed PMC

Brain MRI disease burden and sex differences in cognitive performance of patients with multiple sclerosis

Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis

Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?